利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1221 条记录 (耗时 0.035 秒)

    LIQUID AMNION TRANSPLANT PRODUCT
    63.
    发明申请
    LIQUID AMNION TRANSPLANT PRODUCT 有权

    公开(公告)号：US20210023144A1

    公开(公告)日：2021-01-28

    申请号：US17071570

    申请日：2020-10-15

    申请人： Vivex Biologics Group, Inc.

    发明人： Shabnam Namin ,  Gaëtan Jean-Robert Delcroix

    IPC分类号： A61K35/50

    摘要： A transplant product made from human amniotic fluid has a supernatant from filtered and centrifuged amniotic fluid, the amniotic fluid when recovered aseptically having a clear, translucent to slightly pink or tan color. The supernatant had been taken from the amniotic fluid which had been passed through a 170 to 260 micron blood filter, then centrifuged for 5 minutes or more at 400 g and thereafter the supernatant was separated from a pellet of debris, leaving the biochemical properties intact, wherein the supernatant is cryofrozen in sized cryovials having 0.25 to 2.0 ml of the supernatant at a temperature of −65 degrees or less prior to use and the transplant products method of use. The transplant product contains cellular material, cell fragments, proteins and growth factors maintaining the biochemical properties and is non-immunogenic while having particles up to 170 microns being passable through a 30 gauge syringe for injection.

    Amnion derived therapeutic compositions and methods of use
    64.
    发明授权
    Amnion derived therapeutic compositions and methods of use 有权

    公开(公告)号：US10894066B2

    公开(公告)日：2021-01-19

    申请号：US15257870

    申请日：2016-09-06

    申请人： Amnio Technology LLC

    发明人： Christian Beaudry ,  Bruce Werber ,  Terrell Suddarth

    IPC分类号： A61K35/50

    摘要： Therapeutic compositions are described for the treatment of a variety of conditions including heart, eye, lungs, organs, joints, dermal, nerve, and the like. A therapeutic composition may be a fluid comprising amniotic fluid or micronized amniotic particles. A therapeutic composite may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. In another embodiment, the therapeutic composite is a mixture of micronized amniotic membrane particles combined with an amniotic rich stem cell fluid. An amniotic rich or concentrated stem cell fluid comprises at least 0.5×106 amniotic stem cells per milliliter of fluid or composition. A therapeutic composite may be used to treat any number of conditions through topical application, surgical introduction, and/or injection.

    CELL POPULATION COMPRISING ADHERENT CELLS DERIVED FROM FETAL APPENDAGE, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION
    70.
    发明申请
    CELL POPULATION COMPRISING ADHERENT CELLS DERIVED FROM FETAL APPENDAGE, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION 审中-公开

    公开(公告)号：US20200032205A1

    公开(公告)日：2020-01-30

    申请号：US16575032

    申请日：2019-09-18

    申请人： KANEKA CORPORATION

    发明人： Keita INO ,  Yuta KITA

    IPC分类号： C12N5/073 ,  A61K35/50 ,  A61K35/51 ,  A61K9/00 ,  A61K9/70

    摘要： An object of the present invention is to provide a cell population comprising adherent cells having low differentiation capacity derived from a fetal appendage, methods for producing or using the same, and a pharmaceutical composition comprising the cell population, in particular wherein the proportion of CD73- and CD90-positive adherent cells derived from a fetal appendage is 90% or more; and the cell population satisfies a relative expression level of LFA-3 gene to the expression level of SDHA gene of 1.0 or more, in particular wherein the relative expression level of HAPLN1 gene to the expression level of SDHA gene is 4.0 or more and/or the relative expression level of CCND2 gene to the expression level of SDHA gene is 1.5 or less, in particular wherein the proportion of the STRO-1-negative adherent cells derived from a fetal appendage is 95% or more.